Editas Medicine Dirección

Dirección controles de criterios 3/4

El CEO de Editas Medicine's es Gilmore O’Neill , nombrado en Jun 2022, tiene una permanencia de 1.83 años. compensación anual total es $2.39M, compuesta por 26.8% salario y 73.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $514.78K. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 4.3 años, respectivamente.

Información clave

Gilmore O’Neill

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO	26.8%
Permanencia del CEO	1.9yrs
Participación del CEO	0.1%
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25

Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently

Dec 28

Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles

Dec 15

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Nov 17

Editas: Data Was Eagerly Anticipated But Failed To Impress

Nov 03

Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?

Sep 07

Editas: Gene Therapy Specialist Leading The Way In Eye Disease

Aug 27

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Aug 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gilmore O’Neill en comparación con los beneficios de Editas Medicine?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$2m	US$641k	-US$153m
Sep 30 2023	n/a	n/a	-US$195m
Jun 30 2023	n/a	n/a	-US$206m
Mar 31 2023	n/a	n/a	-US$219m
Dec 31 2022	US$9m	US$356k	-US$220m

Compensación vs. Mercado: La compensación total ($USD2.39M) de Gilmore está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.37M).

Compensación vs. Ingresos: La compensación de Gilmore ha sido consistente con los resultados de la empresa en el último año.

CEO

Gilmore O’Neill (59 yo)

1.9yrs

Permanencia

US$2,392,309

Compensación

Dr. Gilmore O’Neill, M. B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gilmore O’Neill	President	1.9yrs	US$2.39m	0.11% $ 515.7k
Erick Lucera	CFO & Executive VP	less than a year	US$2.69m	0% $ 0
Linda Burkly	Executive VP & Chief Scientific Officer	less than a year	US$1.73m	0% $ 0
Baisong Mei	Executive VP & Chief Medical Officer	1.8yrs	US$1.14m	0.041% $ 182.5k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	11.3yrs	sin datos	sin datos
George Church	Co-Founder & Scientific Advisory Board Member	11.3yrs	sin datos	sin datos
Gregory Whitehead	Executive VP and Chief Technical & Quality Officer	less than a year	sin datos	sin datos
Cristi Barnett	Corporate Communications & Investor Relations	no data	sin datos	sin datos
Charlene Stern	Executive VP & General Counsel	no data	sin datos	sin datos
Linea Aspesi	Executive VP & Chief People Officer	1.2yrs	sin datos	sin datos
Caren Deardorf	Executive VP and Chief Commercial & Strategy Officer	less than a year	sin datos	sin datos

1.2yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de EDIT no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gilmore O’Neill	President	no data	US$2.39m	0.11% $ 515.7k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	no data	sin datos	sin datos
George Church	Co-Founder & Scientific Advisory Board Member	no data	sin datos	sin datos
Emma Reeve	Independent Chairman of the Board	2.7yrs	US$238.24k	0% $ 0
Akshay Vaishnaw	Independent Director	7.8yrs	US$208.06k	0% $ 0
Andrew Hirsch	Independent Director	7yrs	US$210.56k	0.0024% $ 10.9k
Jessica Hopfield	Independent Lead Director	6.3yrs	US$231.07k	0.028% $ 124.2k
Elliott Levy	Independent Director	1.1yrs	sin datos	0% $ 0
David Scadden	Independent Director	5.3yrs	US$213.06k	0% $ 0
Bernadette Connaughton	Independent Director	2.6yrs	US$215.06k	0% $ 0
Meeta Chatterjee	Independent Director	3.4yrs	US$205.56k	0% $ 0

4.3yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de EDIT se considera experimentada (4.3 años de antigüedad promedio).

Editas Medicine Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

President notifies of intention to sell stock

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

Recent updates

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

President notifies of intention to sell stock

Consensus revenue estimates increase by 49%, EPS downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Consensus revenue estimates increase by 25%

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Consensus revenue estimates increase by 14%

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO, Principal Accounting Officer notifies of intention to sell stock

Price target decreased by 8.6% to US$13.06

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Principal Accounting Officer notifies of intention to sell stock

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Price target decreased to US$14.19

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Price target decreased to US$16.73

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Price target decreased to US$25.87

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Editas Medicine started at neutral at BofA due to competition in gene editing programs

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine Q2 2022 Earnings Preview

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Editas Medicine Appoints Baisong Mei, as Chief Medical Officer

Baisong Mei joins Editas Medicine as Chief Medical Officer

Executive VP & Chief Scientific Officer recently sold US$52k worth of stock

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Consensus revenue estimates fall by 12%

Price target decreased to US$31.21

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. Announces Executive Changes, Effective June 1, 2022

Editas Medicine, Inc. Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Executive VP & Chief Business Officer notifies of intention to sell stock

Editas: The Unforeseen Detrimental Effect Of Patent Win

Editas: CRISPR Gene Editing Biotech With Promising Future

Editas Medicine, Inc. Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$37.23

Consensus revenue estimates increase by 15%